---
title: "Salarius Pharmaceuticals (SLRX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SLRX.US.md"
symbol: "SLRX.US"
name: "Salarius Pharmaceuticals"
industry: "Biotechnology"
---

# Salarius Pharmaceuticals (SLRX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.07 | 201/606 | - | - | - |
| PB | 1.26 | 105/606 | 24.07 | 1.26 | 0.83 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-09-09T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.84 |

## References

- [Company Overview](https://longbridge.com/en/quote/SLRX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SLRX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SLRX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.